Abstract:
:Current experimental gene therapy approaches for Parkinson's disease (PD) and dementia with Lewy bodies (DLB) include the use of viral vectors expressing antiapoptosis genes, neurotrophic factors and dopaminergic system enzymes. However, since increasing evidence favors a role for alpha-synuclein accumulation in the pathogenesis of these disorders, an alternative therapy might require the transfer of genes that might block alpha-synuclein accumulation. beta-Synuclein, the nonamyloidogenic homologue of alpha-synuclein, has recently been identified as a potential candidate. Thus, in vivo transfer of genes encoding beta-synuclein might provide a novel approach to the development of experimental treatments for PD and DLB. To assess this possibility and to better understand the mechanisms involved, a lentiviral vector expressing human (h) beta-synuclein (lenti-beta-synuclein) was tested in a transgenic (tg) mouse model of halpha-synuclein aggregation. This study showed that unilateral intracerebral injection of lenti-beta-synuclein reduced the formation of halpha-synuclein inclusions and the accumulation of halpha-synuclein in synapses and ameliorated the neurodegenerative alterations in the tg mice. Both in vivo and in vitro coimmunoprecipitation and immunoblot experiments show that the mechanisms of beta-synuclein neuroprotection involve binding of this molecule to halpha-synuclein and Akt, resulting in the decreased aggregation and accumulation of halpha-synuclein in the synaptic membrane. Together, these data further support a role for beta-synuclein in regulating the conformational state of alpha-synuclein and suggest that this gene transfer approach might have potential for the development of alternative therapies for PD and DLB.
journal_name
Gene Therjournal_title
Gene therapyauthors
Hashimoto M,Rockenstein E,Mante M,Crews L,Bar-On P,Gage FH,Marr R,Masliah Edoi
10.1038/sj.gt.3302349keywords:
subject
Has Abstractpub_date
2004-12-01 00:00:00pages
1713-23issue
23eissn
0969-7128issn
1476-5462pii
3302349journal_volume
11pub_type
杂志文章相关文献
GENE THERAPY文献大全abstract::Synthetic oligonucleotides and DNA fragments of less than 1 kilobase (kb) have been shown to cause site-specific genetic alterations in mammalian cells in culture and in vivo. We have used a lacZ reporter gene system to compare the efficiency of episomal and chromosomal gene repair in human embryonic kidney epithelial...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3302049
更新日期:2003-09-01 00:00:00
abstract::The bystander effect (BSE) is an interesting and important property of the herpes thymidine kinase/ganciclovir (hTK/GCV) system of gene therapy for cancer. With the BSE, not only are the hTK expressing cells killed upon ganciclovir (GCV) exposure but also neighboring wild-type tumor cells. On testing a large number of...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3300784
更新日期:1998-12-01 00:00:00
abstract::Virus-directed enzyme prodrug therapy utilizing the bacterial enzyme nitroreductase delivered by a replication-defective adenovirus vector to activate the prodrug CB1954 is a promising strategy currently undergoing clinical trials in patients with a range of cancers. Similarly, selectively replicating oncolytic adenov...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3302510
更新日期:2005-08-01 00:00:00
abstract::The efficiency of plasmid gene transfer to skeletal muscle can be significantly improved by the application of an electrical field to the muscle following injection of plasmid DNA. However, this electrotransfer is associated with significant muscle damage which may result in substantial loss of transfected muscle fibr...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3301522
更新日期:2001-08-01 00:00:00
abstract::Homologous restriction factor 20 (HRF20, CD59) is one of the complement regulatory factors. In this study, the complement-resistant retroviral vector, which possesses the HRF20 gene as a selection gene, was constructed and examined. The virus-producing cell, transduced with complement-resistant retroviral vector, was ...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3300574
更新日期:1998-02-01 00:00:00
abstract::One factor limiting the ability to modify human repopulating hematopoietic cells genetically with retroviral vectors is the relatively low expression of the cognate viral receptor. We have tested sequential transduction of human hematopoietic cells with an adenoviral vector encoding the ecotropic retroviral receptor f...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3300974
更新日期:1999-08-01 00:00:00
abstract::Advances in islet transplantation have encouraged efforts to create alternative insulin-secreting cells that overcome limitations associated with current therapies. We have recently demonstrated durable correction of murine and porcine diabetes by syngeneic and autologous implantation, respectively, of primary hepatoc...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/gt.2010.12
更新日期:2010-05-01 00:00:00
abstract::Improving the therapeutic potential of adenoviral (Ad) suicide gene therapy has become an area of intense investigation since the inception of gene therapy strategies for cancer treatment. Poor efficiency of gene transfer to target tissues has become one of the most important limitations to Ad-based gene therapy. Sinc...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3300987
更新日期:1999-09-01 00:00:00
abstract::We introduce a lung inflation-fixation protocol to examine the distribution and gene transfer efficiency of fluorescently tagged lipoplexes using fluorescence confocal microscopy within thick lung tissue sections. Using this technique, we tested the hypothesis that factors related to lipoplex distribution were the pre...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3301461
更新日期:2001-06-01 00:00:00
abstract::Adenoviral gene transfer to hematopoietic stem cells (HSCs)/progenitors would provide a new approach to the treatment of hematopoietic diseases and study of the hematopoietic system. We have previously reported that an adenovirus (Ad) vector composed of whole Ad serotype 35 (Ad35), which belongs to subgroup B, shows e...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3302562
更新日期:2005-10-01 00:00:00
abstract::With the long-term goal of developing a gene-based treatment for osteoarthritis (OA), we performed studies to evaluate the equine joint as a model for adeno-associated virus (AAV)-mediated gene transfer to large, weight-bearing human joints. A self-complementary AAV2 vector containing the coding regions for human inte...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/gt.2012.81
更新日期:2013-06-01 00:00:00
abstract::The insertion of suicide genes in donor T lymphocytes constitutes the basis of new approaches aiming at the treatment of the graft-versus-host disease (GVHD), a frequent complication in recipients of allogeneic haematopoietic grafts. In this study we investigated the impact that the ex vivo manipulation required for t...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3302188
更新日期:2004-03-01 00:00:00
abstract::Inhibition of virus replication by means of RNA interference has been reported for several important human pathogens, including human immunodeficiency virus type 1 (HIV-1). RNA interference against these pathogens has been accomplished by introduction of virus-specific synthetic small interfering RNAs (siRNAs) or DNA ...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3302786
更新日期:2006-10-01 00:00:00
abstract::In 2012, we reported that 5 out of 11 subjects in a clinical trial (NCT00372320) administering AdhAQP1 to radiation-damaged parotid glands showed increased saliva flow rates and decreased symptoms over the initial 42 days. AdhAQP1 is a first-generation, E1-deleted, replication-defective, serotype 5 adenoviral vector e...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/gt.2015.55
更新日期:2015-09-01 00:00:00
abstract::Duchenne muscular dystrophy (DMD) is an X-linked, lethal muscular disorder caused by a defect in the DMD gene. AAV vector-mediated micro-dystrophin cDNA transfer is an attractive approach to treatment of DMD. To establish effective gene transfer into skeletal muscle, we examined the transduction efficiency of an AAV v...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3301829
更新日期:2002-12-01 00:00:00
abstract::The gene encoding E. coli nitroreductase (NTR) was expressed in the luminal cells of the mammary gland of transgenic mice using the ovine beta-lactoglobulin promoter. Treatment of NTR expressing animals with the prodrug CB1954 (5-aziridin-1-yl-2-4-dinitrobenzamide) resulted in a rapid and selective killing of this pop...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3300367
更新日期:1997-02-01 00:00:00
abstract::Soluble receptors to vascular endothelial growth factor (VEGF) can inhibit its angiogenic effect. Since angiogenesis is involved in wound repair, we hypothesized that adenovirus-mediated gene transfer of a soluble form of VEGF receptor 2 (Flk-1) would attenuate wound healing in mice. C57Bl/6J and genetically diabetic ...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3302162
更新日期:2004-02-01 00:00:00
abstract::Direct gene transfer for the treatment of human diseases requires a vector which can be administered efficiently, safely and repeatedly. Cationic liposomes represent one of the few examples that can meet these requirements. Currently, more than a dozen cationic liposome formulations have been reported. These liposomes...
journal_title:Gene therapy
pub_type: 杂志文章,评审
doi:
更新日期:1995-12-01 00:00:00
abstract::Most neoplasms do not induce antitumor immune responses that can control tumor growth. Tumor associated antigens (TAAs) are insufficiently immunogenic. A vaccine that augments the immunogenic properties of TAAs could be of importance in the treatment of cancer patients. In an animal model, we prepared a vaccine by tra...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3301765
更新日期:2002-09-01 00:00:00
abstract::We have developed a novel immunostimulatory molecule against tumor cells, composed of an anti-FcgammaRIII (CD16) scFv fused to the platelet-derived growth factor receptor (PDGFR) transmembrane region. This fusion molecule was stably expressed on the tumor cell surface and retained the ability of the parental antibody ...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3301575
更新日期:2001-11-01 00:00:00
abstract::Tissue-specific promoters for gene therapy are typically too big for adeno-associated virus (AAV) vectors; thus, the exploration of small effective non-viral regulatory elements is of particular interest. Wild-type AAV can specifically integrate into a region on human chromosome 19 termed AAVS1. Earlier work has deter...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/gt.2008.134
更新日期:2009-01-01 00:00:00
abstract::We tested the longevity of gene expression provided by autonomously replicating vectors. The vectors contain segments of human genomic DNA that provide efficient replication initiation and sequences derived from Epstein-Barr virus that provide nuclear retention. In order to monitor gene expression, the vectors also ca...
journal_title:Gene therapy
pub_type: 杂志文章
doi:
更新日期:1996-06-01 00:00:00
abstract::Somatic transgenesis can be used to confer endogenous production of proteins with therapeutic properties. One such product, recombinant soluble human CD4 (sCD4), has been shown to be an efficient inhibitor of human immunodeficiency virus 1 (HIV-1) in vitro, but its too short half-life in vivo has impaired long-term cl...
journal_title:Gene therapy
pub_type: 杂志文章
doi:
更新日期:1995-05-01 00:00:00
abstract::Prenatal gene therapy has been considered for Herlitz junctional epidermolysis bullosa (H-JEB), a lethal genodermatosis caused by the absence of any of the three subunits of laminin-5, resulting from birth in widespread blistering and erosions of skin and mucosae. To investigate this strategy in an animal model, adeno...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3302832
更新日期:2006-12-01 00:00:00
abstract::Gene delivery of angiogenic growth factors is a promising approach for the treatment of ischemic cardiovascular diseases. However, success of this new therapeutic principle is hindered by the lack of critical understanding as to how disease pathology affects the efficiency of gene delivery and/or the downstream signal...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3302781
更新日期:2006-09-01 00:00:00
abstract::Intracardiac gene transfer and gene therapy have been investigated with different vector systems. Here we used adeno-associated virus (AAV) vectors to deliver either a reporter gene or a therapeutic gene into the heart of golden Syrian hamsters. The method of gene delivery was direct infusion of the AAV2 vectors into ...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3302078
更新日期:2003-10-01 00:00:00
abstract::In the last two decades, remarkable advances have been made in the development of technologies used to engineer new aptamers and ribozymes. This has encouraged interest among researchers who seek to create new types of gene-control systems that can be made to respond specifically to small-molecule signals. Validation ...
journal_title:Gene therapy
pub_type: 杂志文章,评审
doi:10.1038/gt.2009.81
更新日期:2009-10-01 00:00:00
abstract::The progression of chronic renal diseases is considered as an irreversible process that eventually leads to end-stage renal failure characterized by extensive tissue fibrosis. At present, chronic renal fibrosis is incurable and the incidence of affected patients is on the rise worldwide. In this study, we demonstrate ...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3301545
更新日期:2001-10-01 00:00:00
abstract::Therapeutic RNA interference (RNAi) has emerged as a promising approach for the treatment of many incurable diseases, including cancer, infectious disease or neurodegenerative disorders. Demonstration of efficacy and safety in animal models is necessary before planning human application. Our group and others have prev...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/gt.2011.10
更新日期:2011-07-01 00:00:00
abstract::Mobilized blood CD34+ cells from cancer patients were ex vivo infected by a recombinant adenovirus vector carrying an alkaline phosphatase gene, whose expression is evaluable by flow cytometry. A mean of 40% CD34+ cells were infected by the vector, with high levels of expression of the transgene. Among attempts to imp...
journal_title:Gene therapy
pub_type: 杂志文章
doi:10.1038/sj.gt.3300620
更新日期:1998-04-01 00:00:00